Uncovering Tumor‐Promoting Roles of Activin A in Pancreatic Ductal Adenocarcinoma
Advanced Science · 2023
DOI: 10.1002/advs.202207010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2023. Verfasst von Seok-Yeong Yu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Olson Center for Women's Health, Department of Obstetrics and Gynecology, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NCI NIH HHS, University of Nebraska Medical Center.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers with high incidence rates of metastasis and cachexia. High circulating activin A, a homodimer of inhibin βA subunits that are encoded by INHBA gene, predicts poor survival among PDAC patients. However, it still raises the question of whether activin A suppression renders favorable PDAC outcomes. Here, the authors demonstrate that activin A is abundantly detected in tumor and stromal cells on PDAC tissue microarray and mouse PDAC sections. In orthotopic male mice, activin A suppression, which is acquired by tumor‐targeted Inhba siRNA using cholesterol‐modified polymeric nanoparticles, retards tumor growth/metastasis and cachexia and improves survival when compared to scramble siRNA‐treated group. Histologically, activin A suppression coincides with decreased expression of proliferation marker Ki67 but increased accumulation of α‐SMA high fibroblasts and cytotoxic T cells in the tumors. In vitro data demonstrate that activin A promotes KPC cell proliferation and induces the downregulation of α‐SMA and upregulation of IL‐6 in pancreatic stellate cells (PSC) in the SMAD3‐dependent mechanism. Moreover, conditioned media from activin A‐stimulated PSC promoted KPC cell growth. Collectively, our data provide a mechanistic basis for tumor‐promoting roles of activin A and support therapeutic potentials of tumor activin A suppression for PDAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Olson Center for Women's Health, Department of Obstetrics and Gynecology, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
- Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA.
- Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
- Fred & Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA.
ORCID-Profile: Seok-Yeong Yu, So-Youn Kim
Förderung
- NIGMS NIH HHS
- NCI NIH HHS
- University of Nebraska Medical Center
Zitieren
APA
Yu, S. Y., Luan, Y., Tang, S., Abazarikia, A., Dong, R., Caffrey, T. C., Hollingsworth, M. A., Oupicky, D., & Kim, S. Y. (2023). Uncovering Tumor‐Promoting Roles of Activin A in Pancreatic Ductal Adenocarcinoma. Advanced Science. https://doi.org/10.1002/advs.202207010
Vancouver
Yu SY, Luan Y, Tang S, Abazarikia A, Dong R, Caffrey TC, et al. Uncovering Tumor‐Promoting Roles of Activin A in Pancreatic Ductal Adenocarcinoma. Advanced Science. 2023. doi:10.1002/advs.202207010
BibTeX
@article{Yu2023,
author = {Yu, Seok-Yeong and Luan, Yi and Tang, Siyuan and Abazarikia, Amirhossein and Dong, Rosemary and Caffrey, Thomas C and Hollingsworth, Michael A and Oupicky, David and Kim, So-Youn},
title = {Uncovering Tumor‐Promoting Roles of Activin A in Pancreatic Ductal Adenocarcinoma},
journal = {Advanced Science},
year = {2023},
doi = {10.1002/advs.202207010}
}
EUVIMED